Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a new study, neuroscientists at Oxford University have found that raised blood pressure and diabetes in mid-life alter brain structure to slow thinking speed and memory.

Close up of multiple head and brain MRI imaging

Looking at results from 22,000 volunteers in the UK Biobank who underwent brain scanning, the scientists found that raised blood pressure and diabetes significantly impaired the brain’s cognitive functions, specifically the performance of thinking speed and short-term memory.

Masud Husain, Professor of Neurology and Cognitive Neuroscience at the Nuffield Department of Clinical Neurosciences and lead investigator of the study, said, ‘For blood pressure, every mm of pressure in your arteries counts – even in people who aren’t on any treatment. For people who are on treatment, systolic blood pressures above 140 mm were associated with lower cognitive performance. The higher the pressure, the worse it is.’

The full story is available on the Nuffield Department of Clinical Neurosciences website

This story is also featured on the University of Oxford website

Similar stories

Human challenge trial launches to study immune response to COVID-19

Clinical Trials Coronavirus COVID-19 General

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.